AbbVie says all three zumilokibart dose regimens met primary endpoint in Phase 2 APEX Part B atopic dermatitis study

AbbVie said all three zumilokibart dose regimens met the primary endpoint, with significantly greater EASI-75 response versus placebo at week 16, in the Phase 2 APEX Part B atopic dermatitis study.

Detected & updated continuously · Source: Nebula